kings-college-london
(7)
Martin Taylor and the paperweight that earned its keep
An obsolete prototype sits behind an unusually useful lesson. For Content Guru co-founder Martin Taylor, three decades in communications have meant knowing when to build, when to change direction and when to stop.
Jonathan Talbot and the value of a second look
Before co-founding Mosanna Therapeutics, Jonathan Talbot studied both science and finance. Now the Melodia CEO and 2026 Strüngmann Award winner is building a career around the possibilities that survive a change of plans.
Mark Chaffey and the Applicant Who Never Applied
He spent a decade persuading companies to approach overlooked technical talent. Now the hackajob co-founder is betting that an AI agent can repair a hiring market in which applications are plentiful, attention is scarce, and trust has become the rarest qualification.
Leucid Bio
Leucid Bio is a clinical-stage London biotech developing next-generation CAR-T cell therapies for refractory solid tumors. Spun out of King's College London in 2014 to commercialize two decades of research by Dr John Maher, the company's proprietary Lateral CAR platform redesigns the CAR receptor so its signalling domains sit laterally alongside the cell membrane - mimicking natural immune receptors to boost potency while reducing toxicity. Its lead candidate, LEU011, is an autologous NKG2D-targeting CAR-T therapy now in the Phase I/IIa AERIAL trial for refractory solid tumors.
Henry Adams
Henry Adams is US CEO and Global Head of Capital Markets at TreasurySpring, a London-founded fintech that opens up the multi-trillion dollar wholesale money markets to corporates and institutions. He joined the founding team at the start of 2018 after roughly a decade running secured financing portfolios at RBC and earlier work at BlackRock, and now leads the company's push into the United States from New York. His background sits at the intersection of repo trading, fixed income and product, which he channels into building the market plumbing behind TreasurySpring's Fixed-Term Funds.
Kevin Xu
Kevin Xu is the Chairman and CEO of ClinChoice, a global full-service contract research organization (CRO) with more than 30 years of history, roughly 4,000 staff, and operations across 15+ countries. He arrived in the corner office from the investor's side of the table: for over 15 years he was a Managing Director at Goldman Sachs, where he built and ran the firm's Asia-Pacific Healthcare and Life Sciences investing practice, leading deals across biotech, pharma, medtech, CROs/CDMOs and digital health. Trained in neuroscience and clinical psychology before finance, he is an outspoken advocate for destigmatizing mental illness and an unlikely wake-surfer.
Anne-Laure Le Cunff
Anne-Laure Le Cunff is a French neuroscientist, author, and entrepreneur who burned out at Google, taught herself to code, and built Ness Labs into a 100,000+ reader science-based learning community - all while completing a PhD at King's College London. Her 2025 book 'Tiny Experiments' (Penguin Random House) distills her philosophy: life is a series of experiments and you are the lead scientist. She is now a UKRI-funded postdoctoral researcher studying curiosity and ADHD at KCL, while publishing to 124,000+ Substack subscribers at Hypercurious.